The April 2017 issue of Translational Lung Cancer Research features an article titled Immunotherapy and radiation therapy for malignant pleural mesothelioma written by a group of investigators known within the Meso Foundation’s community: Evan W. Alley, MD, PhD, Sharyn I. Katz, MD, and Keith A. Cengel, MD, PhD, of the University of Pennsylvania, and Charles […]
Michele Carbone, MD, PhD, Director of Thoracic Oncology at the University of Hawaii (UH) Cancer Center, along with his team, have discovered why people carrying mutations of the BAP1 gene are more susceptible to environmental carcinogens, including asbestos, radiation, and ultraviolet light.
BAP1 mutations are seen in approximately 20 percent of all cancers, and Dr. Carbone […]
The American Society of Clinical Oncology (ASCO) held its Annual Meeting on June 2-6, 2017 in Chicago. The Meso Foundation’s CEO, Melinda Kotzian, and Director of Research and Medical Outreach, Gleneara Bates, MS, MSW, PhD (c), had the opportunity to attend the conference and hear the latest news reported in mesothelioma research.
Hedy Lee Kindler, MD, […]
On June 5, Anna Nowak, MD, PhD, of the University of Western Australia and member of the Meso Foundation’s Science Advisory Board, presented phase II results from LUME-Meso, a mesothelioma clinical trial sponsored by Boehringer Ingelheim, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
LUME-Meso is a randomized, double-blind, placebo-controlled trial evaluating […]
This morning, Arnaud Scherpereel, MD, PhD, head of the Pulmonary and Thoracic Oncology Department at the University Hospital of Lille in France, presented the results of the IFCT-1501 MAPS-2 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study was sponsored by the French Cooperative Thoracic Intergroup (IFCT) with drugs and […]